|Tested species reactivity||Virus|
|Published species reactivity||Virus, Human|
|Host / Isotype||Mouse / IgG2a, kappa|
|Storage buffer||PBS, pH 7.4, with 0.2% BSA|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Immunofluorescence (IF)||Assay Dependent|
|Immunohistochemistry (IHC)||2-4 µg/ml|
|Immunoprecipitation (IP)||2 µg/ml|
|Western Blot (WB)||1 µg/mL|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
MA5-13648 targets Adenovirus Type 2 E1A in IF, IHC, IP, and WB applications and shows reactivity with Virus samples.
The MA5-13648 immunogen is adenovirus.
The adenovirus early gene product E1A is a potent stimulator of cellular proliferation, which when overexpressed can overcome the growth-inhibitory effects of TGF-beta. The E1A region encodes a series of related proteins (35-46kDa) with multifuctional capabilities and form a specific complex with the retinoblastoma tumor suppressor gene product (Rb protein). The E1A and E1B regions together comprise the transforming region of adenovirus. While expression of E1A alone is sufficient to immortalize primary cells, complete transformation requires the additional expression of the E1B region.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
2-aminopurine enhances the oncolytic activity of an E1b-deleted adenovirus in hepatocellular carcinoma cells.
MA5-13648 was used in western blot to study the ability of 2-aminopurine to increase the anti-cancer activity of an adenovirus deleted for the e1b and VA-RNA genes
|Sharon D,Schümann M,MacLeod S,McPherson R,Chaurasiya S,Shaw A,Hitt MM||PloS one (8:null)||2013|
Modification of the p53 transgene of a replication-competent adenovirus prevents mdm2- and E1b-55kD-mediated degradation of p53.
MA5-13648 was used in western blot to investigate the oncolytic efficacy of a replication-competent adenovirus with modified p53 trangene
|Sauthoff H,Pipiya T,Chen S,Heitner S,Cheng J,Huang YQ,Rom WN,Hay JG||Cancer gene therapy (13:686)||2006|
Hypoxia reduces adenoviral replication in cancer cells by downregulation of viral protein expression.
MA5-13648 was used in western blot to study the role of hypoxia in downregulating viral protein expression in cancer cells
|Pipiya T,Sauthoff H,Huang YQ,Chang B,Cheng J,Heitner S,Chen S,Rom WN,Hay JG||Gene therapy (12:911)||2005|
Gene therapy with secretory leukoprotease inhibitor promoter-controlled replication-competent adenovirus for non-small cell lung cancer.
MA5-13648 was used in western blot to develop an adenovirus vector for gene therapy of non-small cell lung cancer
|Maemondo M,Saijo Y,Narumi K,Kikuchi T,Usui K,Tazawa R,Matsumoto K,Nakamura T,Sasaki K,Takahashi M,Niitsu Y,Nukiwa T||Cancer research (64:4611)||2004|
Oncolytic replication-competent adenovirus suppresses tumor angiogenesis through preserved E1A region.
MA5-13648 was used in immunocytochemistry to study the mechanism by which oncolytic replication-competent adenovirus suppresses tumor angiogenesis
|Saito Y,Sunamura M,Motoi F,Abe H,Egawa S,Duda DG,Hoshida T,Fukuyama S,Hamada H,Matsuno S||Cancer gene therapy (13:242)||2006|
E2F transcriptional activation requires TRRAP and GCN5 cofactors.
MA5-13648 was used in immunoprecipitation to study the role of TRRAP and GCN5 acetyltransferase as cofactors in the transcriptional activation of E2F
|Lang SE,McMahon SB,Cole MD,Hearing P||The Journal of biological chemistry (276:32627)||2001|